Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zotiraciclib,Temozolomide
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adastra Pharmaceuticals to Present at LifeSci Partners' Summer Symposium
Details : Adastra's clinical candidate, zotiraciclib, is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2020
Lead Product(s) : Zotiraciclib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zotiraciclib
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : European Organisation for Research and Treatment of Cancer
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2017
Lead Product(s) : Zotiraciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : European Organisation for Research and Treatment of Cancer
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2012
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2010